Episode

E119: Teclistamab for Rheumatology Writ Large

Podcast: The Evidence Based Rheumatology Podcast
Published: Feb 10, 2025
Duration seconds: 652
Processing state: not_requested
Canonical source: https://msputman.podbean.com/e/e119-teclistamab-for-rheumatology-writ-large/
Audio: https://mcdn.podbean.com/mf/web/hnxheudkwe8dnbc7/e119.mp3
JSON: /v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e119-teclistamab-for-rheumatology-writ-large
Markdown: /podcast/the-evidence-based-rheumatology-podcast-1130175/e119-teclistamab-for-rheumatology-writ-large.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e119-teclistamab-for-rheumatology-writ-large/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e119-teclistamab-for-rheumatology-writ-large.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

One of my rare case-report podcasts, a topic that I typically avoid. The craze about CAR-T has also made me a little crazy, though, so I wanted to share what I think may be the ultimate destination for "more B cell depletion than rituximab" strategies. Article: https://www.nejm.org/doi/full/10.1056/NEJMc2407150